A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

← catalyst calendar

NCT07733180 · readout in 558 d

Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.

Phase

Phase 2

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

30estimated

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-08-31

estimated

When the study began enrolling

Primary completion

2028-02-28

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-02-28

estimated

The whole study's end, after follow-up

First posted

2026-07-29

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Advanced Esophageal Squamous Cell Carcinoma
Metastatic Esophageal Squamous Cell Carcinoma

Interventions

Drug: Tislelizumab
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-fluorouracil (5-FU)

Primary outcomes

what the primary-completion date above is the date OF

Serum Concentrations of Tislelizumab at Specified Time Points

measured Approximately 12 months

Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

measured Approximately 12 months

Overall Response Rate (ORR)Assessed by Independent Review Committee (IRC)

measured Approximately 12 months

Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed